Yale Bulletin and Calendar

April 25, 2003|Volume 31, Number 27



BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Research shows antipsychotic drug risperidone may reduce severity of Tourette's symptoms

A study by Yale researchers suggests that the atypical antipsychotic drug risperidone reduces tic symptoms in children and adults with Tourette syndrome (TS).

"These results suggest that risperidone is safe and effective for short-term treatment of tics in children or adults with Tourette syndrome," says lead author Lawrence Scahill, associate professor in the Yale School of Nursing and the Yale Child Study Center. "Longer-term studies are needed to evaluate the durability of efficacy and safety over time."

Symptoms of TS include persistent motor and phonic tics affecting one to eight per 1,000 school-age children. The tics include jerking movements of the body and involuntary vocalizations. Common motor tics include eye blinking, facial movements, head jerking or shrugging. Common vocal tics include grunting, coughing, throat clearing or snorting. In many cases the tics are mild and may not require treatment with medication. When tics occur frequently, in combinations or involve more disruptive movements or sounds, medication is prescribed. Until recently, few new medications were available for the treatment of tics.

Published in the current issue of Neurology, the Yale study looked at 34 patients (26 children and eight adults) who were randomly assigned to receive either risperidone or a placebo for eight weeks. The medication or a placebo was administered on a gradually increasing dose to minimize side effects over the first four weeks of the study. Patients were seen every other week to evaluate response and adjust the dose. The primary outcome measure was based on patient and family interviews by a clinician who was blind to the treatment assignment.

After eight weeks of treatment, the 16 subjects on risperidone showed a 32% reduction in tic severity. The placebo group showed only a 7% reduction. Scahill says this difference was statistically and clinically significant.

Similar results were observed when the children were evaluated separately. The 12 children randomized to risperidone showed a 36% reduction in tic symptoms compared to an 11% decrease in the 14 children on placebo. The medication was generally well tolerated.

"Of particular note is that there were no neurological side effects such as dystonia, dyskinesia or restlessness, which are often seen in the traditional antipsychotic medications that are commonly used for the treatment of tics in TS," says Scahill.

Risperidone, which was developed for the treatment of adults with schizophrenia, was introduced in 1994. This study was the second to compare risperidone and placebo in a randomized clinical trial.

Collaborators on the study included Yale Child Study Center researchers James Leckman, Robert Schultz, Lily Katsovich and Bradley Peterson, who is now at Columbia University.

The study was funded in part by the following organizations: the Tourette Syndrome Program Project and the Research Units on Pediatric Psychopharmacology of the National Institutes of Health; the Children's Clinical Research Center and Janssen Pharmaceutica Products, LP.

-- By Karen Peart


T H I SW E E K ' SS T O R I E S

Yale cited for its 'dramatic steps' in internationalization

Study suggests there are more genes in the human genome than predicted

Inclusion is key to economic success of developing countries, says expert

Levin book explores role of a university

UNIVERSITY TEACH-INS ON THE WAR WITH IRAQ

Study shows Icon molecule may offer key . . .

Unique argument pays off for winning Law School students

Alumni to focus on Yale Engineering

Works by 'Cha-tic' offer detailed view of Native American life

Play explores transformations brought about by 'Changes of Heart'

Kumpati Narendra lauded for his work in engineering

Guggenheim Fellowships are awarded to five faculty members

Research shows antipsychotic drug risperidone may reduce . . .

F&ES events look at the role of fire in forest management

Research reveals dramatic rise in number of doctors pursuing . . .

Juniors honored for 'good labor in the world' and musical gifts

Richard Sewall dies, was first master of Ezra Stiles College

Pioneering immunobiologist Dr. Charles Janeway Jr. dies

New award will honor creativity of School of Nursing students

Concert to help raise funds for year-round, overflow homeless shelter

Campus Notes


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Yale Scoreboard|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs Home|News Releases| E-Mail Us|Yale Home Page